{
  "story_id": "8efd6149ed7062ecc4cac4a6b6cd3104",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-20T16:40:01.000Z",
  "content_hash": "cd2600263c0256206bd041370b332cb8757e939fe8f02ca155fc1de6e39bfa86",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "ED drug class candidate AR1001 slowed Alzheimer's symptoms in trial subset",
    "dek": "AriBio reported phase 3 trial results for experimental Alzheimer's drug AR1001.",
    "prose": "In the trial subset of 604 participants not taking other Alzheimer's medications, AR1001 was reported to slow symptom worsening by 31% compared to placebo over one year. [^1]\n\nSouth Korean biotechnology company AriBio announced phase 3 trial results for experimental Alzheimer's drug AR1001 at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, United States. [^2] Prof. Dr. A. Oğuz Tanrıdağ emphasized that early specialist assessment improves Alzheimer disease management outcomes. [^3] Prof. Dr. A. Oğuz Tanrıdağ stated that retaining old memories perfectly while being unable to recall recent events is a key Alzheimer warning sign. [^4]\n\nProf. Dr. A. Oğuz Tanrıdağ, NPİSTANBUL Hospital neurologist, stated that normal forgetting is distinct from persistent pathological forgetfulness. [^5] Across the full trial cohort, AR1001 did not produce statistically reliable benefits for Alzheimer's symptoms. [^6] The AR1001 phase 3 trial enrolled 1535 people with early Alzheimer's disease across 13 countries, with participants receiving either 30mg AR1001 or placebo daily for one year. [^7]\n\nProf. Dr. A. Oğuz Tanrıdağ listed time/place disorientation, language difficulty, and impaired daily tasks as early Alzheimer signs. [^8]",
    "cited": "[{\"statement\":\"In the trial subset of 604 participants not taking other Alzheimer's medications, AR1001 was reported to slow symptom worsening by 31% compared to placebo over one year.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T16:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html\"},{\"statement\":\"South Korean biotechnology company AriBio announced phase 3 trial results for experimental Alzheimer's drug AR1001 at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, United States.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T16:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html\"},{\"statement\":\"Prof. Dr. A. Oğuz Tanrıdağ emphasized that early specialist assessment improves Alzheimer disease management outcomes.\",\"source\":\"Ekonomim\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T11:33:00.000Z\",\"publisher_count\":1,\"sources\":[\"Ekonomim\"],\"url\":\"https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447\"},{\"statement\":\"Prof. Dr. A. Oğuz Tanrıdağ stated that retaining old memories perfectly while being unable to recall recent events is a key Alzheimer warning sign.\",\"source\":\"Ekonomim\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T11:33:00.000Z\",\"publisher_count\":1,\"sources\":[\"Ekonomim\"],\"url\":\"https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447\"},{\"statement\":\"Prof. Dr. A. Oğuz Tanrıdağ, NPİSTANBUL Hospital neurologist, stated that normal forgetting is distinct from persistent pathological forgetfulness.\",\"source\":\"Ekonomim\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T11:33:00.000Z\",\"publisher_count\":1,\"sources\":[\"Ekonomim\"],\"url\":\"https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447\"},{\"statement\":\"Across the full trial cohort, AR1001 did not produce statistically reliable benefits for Alzheimer's symptoms.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T16:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html\"},{\"statement\":\"The AR1001 phase 3 trial enrolled 1535 people with early Alzheimer's disease across 13 countries, with participants receiving either 30mg AR1001 or placebo daily for one year.\",\"source\":\"Medical Xpress\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T16:40:01.000Z\",\"publisher_count\":1,\"sources\":[\"Medical Xpress\"],\"url\":\"https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html\"},{\"statement\":\"Prof. Dr. A. Oğuz Tanrıdağ listed time/place disorientation, language difficulty, and impaired daily tasks as early Alzheimer signs.\",\"source\":\"Ekonomim\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T11:33:00.000Z\",\"publisher_count\":1,\"sources\":[\"Ekonomim\"],\"url\":\"https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "90070a05c6a78a32df74ecfc36f271b6fde6948e15fbfd42f78a9d0038a06286",
    "cursor_from": "ingest:raw_newsroomfloor.stories:90070a05c6a78a32",
    "cursor_to": "ingest:raw_newsroomfloor.stories:90070a05c6a78a32",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "8-jnPfmq3wQMiwCy3sPFPWsgrB54VJcNNdz6NLVZJUwhgzEChi56OL-91V2xAg3LRiZlebuQnGKEWeCIHfLCDQ",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "5794d34b3f94301c1977c5eec13fe41e",
      "thread_id": "d0aa08749d19e273497e52d9da54adf5",
      "thread_label": "Alzheimer's disease",
      "novelty": "UPDATE",
      "content_hash": "4c23649f4e501dbc72d8eec690b20df7e329ac6866cf8269c81060174ab85cf0",
      "compose": 3,
      "last_published_at": "2026-11-20T16:40:01.000Z",
      "read_receipt": {
        "slice_hash": "c64b4c2a53751a6a3ea71bd41523f89a0d1ea74d3f3da6964683a5ac229dc983",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMjBUMTQ6NDE6NTIuMDAwWiIsImlkIjoiN2Y3ZmM0YjIzZDU2NTg4YjJkYjkzOTdmNjA1MDQwMWEiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMjBUMTc6Mzc6MTAuMDAwMDAwWiIsImlkIjoiOWVlYmVlZjgyMWM1MTExMmU1NzI0MDA2ZWNkYzhjZjEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 44,
        "window_days": 3,
        "bytes_scanned": 2475099,
        "credits": 3.52,
        "price_per_100_rows": 8,
        "sig": "s7lKweKXlGKIUMewVGaSHG4dXxVrHonHJ3jEz9YTSepsA-QA9blJy4IWgfbPg973e-oS7wkEiuRx3J_jPe6UCA",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-20T18:37:07.521Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "In the trial subset of 604 participants not taking other Alzheimer's medications, AR1001 was reported to slow symptom worsening by 31% compared to placebo over one year.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "South Korean biotechnology company AriBio announced phase 3 trial results for experimental Alzheimer's drug AR1001 at the 19th Clinical Trials on Alzheimer's Disease conference in Boston, United States.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "Prof. Dr. A. Oğuz Tanrıdağ emphasized that early specialist assessment improves Alzheimer disease management outcomes.",
      "source": "Ekonomim",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "Prof. Dr. A. Oğuz Tanrıdağ stated that retaining old memories perfectly while being unable to recall recent events is a key Alzheimer warning sign.",
      "source": "Ekonomim",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Prof. Dr. A. Oğuz Tanrıdağ, NPİSTANBUL Hospital neurologist, stated that normal forgetting is distinct from persistent pathological forgetfulness.",
      "source": "Ekonomim",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Across the full trial cohort, AR1001 did not produce statistically reliable benefits for Alzheimer's symptoms.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "The AR1001 phase 3 trial enrolled 1535 people with early Alzheimer's disease across 13 countries, with participants receiving either 30mg AR1001 or placebo daily for one year.",
      "source": "Medical Xpress",
      "instrument": "News",
      "claim_key": null,
      "url": "https://medicalxpress.com/news/2026-11-erectile-dysfunction-drug-alzheimer.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "Prof. Dr. A. Oğuz Tanrıdağ listed time/place disorientation, language difficulty, and impaired daily tasks as early Alzheimer signs.",
      "source": "Ekonomim",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.ekonomim.com/saglik/alzheimer-sadece-unutkanlik-yapmiyor-iste-gozden-kacan-diger-sinyaller-haberi-932447",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}